Table 1.

Association between YTHDF1 polymorphisms and hepatoblastoma risk

Genotype	Cases (N=313)	Controls (N=1444)	P a	Crude OR (95% CI)	P	Adjusted OR (95% CI) b	P b
rs6011668 C>T (HWE=0.882)
CC	221 (70.61)	1047 (72.51)		1.00		1.00
CT	83 (26.52)	366 (25.35)		1.07 (0.81-1.42)	0.614	1.08 (0.82-1.42)	0.603
TT	9 (2.88)	31 (2.15)		1.38 (0.65-2.93)	0.408	1.35 (0.63-2.87)	0.441
Additive			0.405	1.11 (0.87-1.40)	0.405	1.10 (0.87-1.40)	0.413
Dominant	92 (29.39)	397 (27.49)	0.497	1.10 (0.84-1.44)	0.497	1.10 (0.84-1.44)	0.495
Recessive	304 (97.12)	1413 (97.85)	0.433	1.35 (0.64-2.86)	0.435	1.32 (0.62-2.81)	0.469
rs6090311 A>G (HWE=0.240)
AA	142 (45.37)	558 (38.64)		1.00		1.00
AG	133 (42.49)	696 (48.20)		0.75 (0.58-0.98)	0.032	0.75 (0.58-0.98)	0.033
GG	38 (12.14)	190 (13.16)		0.79 (0.53-1.17)	0.231	0.79 (0.53-1.17)	0.240
Additive			0.066	0.84 (0.70-1.01)	0.066	0.84 (0.70-1.01)	0.070
Dominant	171 (54.63)	886 (61.36)	0.028	0.76 (0.59-0.97)	0.028	0.76 (0.59-0.97)	0.029
Recessive	275 (87.86)	1254 (86.84)	0.627	0.91 (0.63-1.32)	0.627	0.92 (0.63-1.33)	0.643
Combined effect of protective genotypes c
0	8 (2.56)	31 (2.15)		1.00		1.00
1	135 (43.13)	527 (36.50)		0.99 (0.45-2.21)	0.986	1.01 (0.45-2.26)	0.976
2	170 (54.31)	886 (61.36)	0.026	0.74 (0.34-1.65)	0.465	0.76 (0.34-1.68)	0.497
0-1	143 (45.69)	558 (38.64)		1.00		1.00
2	170 (54.31)	886 (61.36)	0.021	0.75 (0.59-0.96)	0.021	0.75 (0.59-0.96)	0.022

OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium.

^a χ² test for genotype distributions between hepatoblastoma patients and cancer-free controls.

^b Adjusted for age and gender.

^c Protective genotypes were carriers with rs6011668 CC/CT, and rs6090311 AG/GG genotypes.